Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2011-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2011.01.021PMID 21295470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.

  2011cited by this paper
• Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

  2010cited by this paper
• Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1.

  2010cited by this paper
• CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

  2010cited by this paper
• Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication

  2010cited by this paper
• Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.

  2010cited by this paper
• Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

  2010cited by this paper
• Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel

  2010cited by this paper
• Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents.

  2010cited by this paper
• Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1.

  2009cited by this paper
• Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

  2009cited by this paper
• Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

  2009cited by this paper
• Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1.

  2009cited by this paper
• Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

  2009cited by this paper
• Raltegravir with optimized background therapy for resistant HIV-1 infection.

  2008cited by this paper
• Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors

  2008cited by this paper
• Maraviroc for previously treated patients with R5 HIV-1 infection.

  2008cited by this paper
• Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition

  2008cited by this paper
• Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

  2004cited by this paper
• Enzymatic resolution of bicyclic 1-heteroarylamines using Candida antarctica lipase B.

  2003cited by this paper
• Concise preparation of amino-5,6,7,8-tetrahydroquinolines and amino-5,6,7,8-tetrahydroisoquinolines via catalytic hydrogenation of acetamidoquinolines and acetamidoisoquinolines.

  2002cited by this paper
• ATP-dependent Activation of the Intermediate Conductance, Ca2+-activated K+ Channel, hIK1, Is Conferred by a C-terminal Domain*

  2001cited by this paper
• Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor*

  2001cited by this paper
• The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment.

  1999cited by this paper
• HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

  1996cited by this paper
• CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5

  1996cited by this paper

• Ligand-Based Modeling of CXC Chemokine Receptor 4 and Identification of Inhibitors of Novel Chemotypes as Potential Leads towards New Anti-COVID-19 Treatments.

  2022cites this paper
• Medicinal chemistry strategies toward host targeting antiviral agents

  2020cites this paper
• Synthetic Activators of Cell Migration Designed by Constructive Machine Learning

  2019cites this paper
• Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.

  2019cites this paper
• Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.

  2018cites this paper
• Synthesis of spiro-linked quinolinone-pyrrolidine/pyrrolo[1,2-c]thiazole-oxindole/acenaphthalene hybrids via multi-component [3 + 2] cycloaddition

  2018cites this paper
• SYNTHESIS AND ANALYSIS OF PYRIDINE DERIVATIVES AS SMALL MOLECULE ANTAGONISTS OF CXCR4

  2018cites this paper
• Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.

  2018cites this paper
• The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.

  2018cites this paper
• Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies

  2017cites this paper
• Synthesis & Evaluation Of Thiophene Derivatives As CXCR4 Antagonists

  2017cites this paper
• Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.

  2016cites this paper
• Mécanismes de résistance aux inhibiteurs de CCR5

  2015cites this paper
• AMD3100/CXCR4 Inhibitor

  2015cites this paper
• Resistance against inhibitors of HIV-1 entry into target cells

  2015cites this paper
• HIV-1 Entry Inhibitor Resistance

  2014cites this paper
• Toward Tripeptidomimetic CXCR4 Antagonists: Design, Synthesis, Biological Evaluation, and Binding Mode Studies

  2014cites this paper
• Progress in studies of structure, mechanism and antagonists interaction of GPCR co-receptors for HIV.

  2014cites this paper
• Entry inhibitors and their use in the treatment of HIV-1 infection.

  2013cites this paper
• Highly SpecIfic and Sensitive Pharmacophore Model for Identifying CXCR4 Antagonists. Comparison with Docking and Shape-Matching Virtual Screening Performance

  2013cites this paper
• Small Molecule Inhibitors of CXCR4

  2013cites this paper
• Imaging agents for the chemokine receptor 4 (CXCR4).

  2012cites this paper
• Novel compounds inhibiting HIV infection, breast cancer metastasis, and bacterial growth

  2012cites this paper
• Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

  2011cites this paper